Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
DCTH Market Cap: $5.2M. SMH.
Anyone who thinks DCTH PPS will not rally, or that current shareholders will lose everything as a result of a reverse split that may (or may not) happen is smoking crack.
Highlights from the fourth quarter of 2017 and recent weeks include:
Revenue from European sales for 2017 increased 35% to $2.7 million from $2.0 million in 2016;
Satisfaction of all obligations under the privately placed senior secured convertible notes issued to two institutional investors in June 2016;
Completed a $5.0 million capital raise in February 2018;
Modified the Special Protocol Agreement (SPA) with the U.S. Food and Drug Administration (FDA) for the Company’s Phase 3 clinical trial of Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS) to treat patients with hepatic dominant ocular melanoma (OM);
Announced that the independent Data Safety Monitoring Board (DSMB) of the Phase 3 FOCUS clinical trial recommended that the study continue without modification; Reported the 500th CHEMOSAT treatment in Europe;
Announced results from a multi-center analysis of Delcath’s Percutaneous Hepatic Perfusion (PHP) therapy in the peer-reviewed Journal of Surgical Oncology; largest data set outside of clinical trial showed manageable toxicity and overall median overall survival of 15.3 months, and;
Secured a commercial supply of melphalan through an agreement with Tillomed Laboratories for use with the company’s CHEMOSAT® Delivery System for Melphalan, where it is marketed in Europe for the treatment of a wide range of cancers of the liver.
Economies of Scale, ladies!
Delcath to Present at Oppenheimer 28th Annual Healthcare Conference
A live webcast of the presentation will be available at www.delcath.com/investors-events, and a replay will be available at the same address approximately one hour after the presentation for approximately 90 days.
http://www.globenewswire.com/news-release/2018/03/19/1442327/0/en/Delcath-to-Present-at-Oppenheimer-28th-Annual-Healthcare-Conference.html
How can you be so obtuse?
POTENTIAL RS. EOM.
ITS TIME FOR GREEN
DCTH EUROPA.
Earnings up 37% year over year. DCTH is just warming up.
Delcath Announces Commercial Supply Agreement for Melphalan Hydrochloride for Injection with Tillomed Laboratories
“We are particularly pleased to be working with a supplier of Tillomed’s caliber and experience as it establishes firm control over our melphalan supply chain in Europe and, over time, will provide economies of scale", noted Jennifer K. Simpson, Ph.D., MSN, CRNP President and CEO of Delcath.
ECONOMIES OF SCALE: A proportionate saving in costs gained by an increased level of production.
Read: Additional supply is needed to match the increased demand for the CHEMSAT therapy.
http://delcath.com/investors-news/
------------------------------------------------------------------------
Delcath Systems Offers Significant Upside For Risk-Tolerant Investors
Delcath Systems is developing unique, proprietary medical products which are aimed at treating the unmet needs of patients with liver cancer.
There has been significant regulatory and commercial progress in Europe as well as substantial clinical trial progress in the United States.
Recently released clinical data has provided shareholders with renewed optimism.
Significant potential upside awaits investors who are willing to tolerate the risk associated with this investment.
Delcath Systems (DCTH) offers tremendous potential upside for investors who are willing to tolerate a high degree of risk. Shareholders stand to reap a financial windfall if the company manages to successfully navigate clinical, regulatory, and financial hurdles. Delcath Systems' rock-bottom share price provides investors with the opportunity to initiate a large position in the company and take advantage of this uniquely asymmetric risk/reward opportunity.
https://seekingalpha.com/article/4086621-delcath-systems-offers-significant-upside-risk-tolerant-investors
-----------------------------------------------------------------------
Delcath’s 500th Commercial CHEMOSAT Treatment in Europe:
This is a meaningful milestone for Delcath, one that speaks to the belief physicians in Europe have developed in our product and this therapy for certain types of liver cancers. Our commercialization efforts in Europe have established a considerable body of published and presented research data that demonstrates the safety and efficacy of this therapy in appropriate patients. Further, Dutch Health Authorities recently included CHEMOSAT treatment in their published guidelines for ocular melanoma liver metastases, a step toward potential reimbursement coverage of CHEMOSAT in the Dutch market. We continue to leverage this experience to validate the safety and efficacy of the melphalan/Hepatic Delivery System (CHEMOSAT) in our clinical trials.”
http://delcath.com/reuters-news/?id=2330074
---------------------------------------------------------------------
Positive Results From a Multi-Center Analysis of Delcath PHP Therapy Published in Journal of Surgical Oncology
The study authors further concluded that “results clearly demonstrate that PHP Therapy appears to be an effective means of obtaining rapid intrahepatic disease control, and is a sensible option in patients with predominant liver disease.” Researchers said their results support the use of PHP Therapy in an integrated approach to the management of metastatic ocular melanoma, and looked to the company’s Phase 3 FOCUS Trial to further quantify the benefit and optimize treatment strategies for these patients.
https://www.otcmarkets.com/stock/DCTH/news/Positive-Results-From-a-Multi-Center-Analysis-of-Delcath-PHP-Therapy-Published-in-Journal-of-Surgical-Oncology?id=179899
------------------------------------------------------------------------
Delcath Announces Preliminary Safety Analysis for Phase 3 Focus Trial
“The DSMB’s recommendation to proceed without modification with the FOCUS Trial as planned confirms our own observations of the safety profile of PHP therapy based on prior research and our commercial experience with CHEMOSAT in Europe,” said Jennifer K. Simpson, Ph.D., MSN, CRNP President and CEO of Delcath. “Importantly, this initial independent evaluation of the safety profile of melphalan/HDS used the Generation Two filter configuration of the device and the current version of the procedure protocol, and so provides confidence in both our product and procedure. Given that safety concerns with the previous generation product and procedure were the primary issue in the FDA’s previous assessment, we are pleased to have successfully passed this important milestone.
http://delcath.com/reuters-news/?id=2323336
------------------------------------------------------------------------
Delcath Announces Third Quarter 2017 Financial Results
Highlights from the third quarter of 2017 and recent weeks include:
• Revenue for the third quarter of 2017 increased 75% to $0.7 million from $0.4 million in the prior-year quarter;
• Revenue for the first nine months of 2017 increased 53% to $2.0 million from $1.3 million in the prior-year period;
• Medical University of Hannover achieved its 100th CHEMOSAT treatment milestone; over 450 commercial CHEMOSAT procedures have been performed in Europe;
• Positive results from a single institution study of CHEMOSAT filtration efficiency were presented at 2017 CIRSE annual meeting in September
http://delcath.com/reuters-news/?id=2317164
------------------------------------------------------------------------
Delcath Enhances Board of Directors With Appointment of Industry Veteran, Dr. Simon Pedder
NEW YORK, Nov. 20, 2017 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTHD), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that Simon Pedder, Ph.D., a scientist and pharmaceutical executive with a greater than 30-year career in drug development, has joined the Delcath Board of Directors effective November 14, 2017.
Dr. Pedder currently serves as Chief Business and Strategy Officer at Athenex, Inc., a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer.During his long career in drug development, Dr. Pedder has held several leadership positions including President and CEO of Cellectar Biosciences, President and CEO of Chelsea Therapeutics, Executive Officer and Vice President of Oncology Pharma Business at Hoffmann-LaRoche, Life Cycle Leader and Global Project Leader of Pegasys/IFN and Head of the Hepatitis Franchise at Hoffmann-LaRoche.
http://delcath.com/reuters-news/?id=2317872
Delcath Announces Satisfaction of 2016 Convertible Note
DCTH is now debt free.
http://delcath.com/investors-news/
------------------------------------------------------------------------
This junk software has been for sale on Amazon since December of 2015.
Why haven’t we heard about a single sale? Because no one has purchased it in the 3 years it’s been available.
Download and install if you like. I did. Do some due diligence and check it out.
FACT: You’ll see how clunky it is. And the interface? Spartan.
CEO= clown.
1. DCTH FY 2017 EARNINGS HIGHLIGHTS
• Revenue from European sales for 2017 increased 35%
• Satisfaction of all obligations under the privately placed senior secured convertible notes issued to two institutional investors in June 2016 – DCTH IS DEBT FREE;
• Completed a $5.0 million capital raise in February 2018;
• Modified the Special Protocol Agreement (SPA) with the U.S. Food and Drug Administration (FDA) for the Company’s Phase 3 clinical trial of Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS) to treat patients with hepatic dominant ocular melanoma (OM);
• Announced that the independent Data Safety Monitoring Board (DSMB) of the Phase 3 FOCUS clinical trial recommended that the study continue without modification; Reported the 500th CHEMOSAT treatment in Europe;
• Announced results from a multi-center analysis of Delcath’s Percutaneous Hepatic Perfusion (PHP) therapy in the peer-reviewed Journal of Surgical Oncology; largest data set outside of clinical trial showed manageable toxicity and overall median overall survival of 15.3 months, and;
• Secured a commercial supply of melphalan through an agreement with Tillomed Laboratories for use with the company’s CHEMOSAT® Delivery System for Melphalan, where it is marketed in Europe for the treatment of a wide range of cancers of the liver.
https://finance.yahoo.com/news/delcath-announces-2017-financial-results-130000468.html
2. DCTH IS TELEGRAPHING
Delcath Announces Commercial Supply Agreement for Melphalan Hydrochloride for Injection with Tillomed Laboratories
“We are particularly pleased to be working with a supplier of Tillomed’s caliber and experience as it establishes firm control over our melphalan supply chain in Europe and, over time, will provide economies of scale", noted Jennifer K. Simpson, Ph.D., MSN, CRNP President and CEO of Delcath.
ECONOMIES OF SCALE: A proportionate saving in costs gained by an increased level of production.
Read: Additional supply is needed to match the increased demand for the CHEMSAT therapy.
10K CONFIRMATION:
During 2017, Delcath added 7 employees to support clinical trial implementations in the EU and United States and to meet the demands of commercial sales
http://delcath.com/investors-news/
3. OTHER 10K HIGHLIGHTS
With the establishment of a ZE code for CHEMOSAT, the procedure is now permanently represented in the DRG catalog in Germany.
In the Netherlands CHEMOSAT has been performed at the Netherlands Cancer Institute in 2013 and at Leiden University Medical Centre since 2014. In June 2017 the Medical Oncology National Treatment Guidelines for Uveal Melanoma were updated and now include recommendations to consider CHEMOSAT in the treatment of liver metastases.
4. ICC. In March 2017 we announced another SPA agreement with the FDA for the design of a new pivotal trial of Melphalan/HDS to treat patients with intrahepatic cholangiocarcinoma (ICC). Under the SPA, the Pivotal ICC Trial will enroll approximately 295 ICC patients at approximately 40 clinical sites in the U.S. and Europe. The SPA agreement for this trial indicates that the pivotal trial design adequately addresses objectives that, if met, would support regulatory requirements for approval of Melphalan/HDS in ICC.
5. DARK HORSE. U.S. Right to Try Legislation. Passed Senate. Failed House 3/12/18 (259-140). House leadership will re-submit bill for vote requiring only simple majority. Republicans have simple majority in House. This will pass in time before mid-term elections, IMO.
So what does this mean?
Ocular Melanoma and Intrahepatic cholangiocarcinoma (ICC) are among the most prevalent and lethal forms of cancer. Approval of RIGHT TO TRY would put Ocular Melanoma (FOCUS trial) and Intrahepatic Cholangiocarcinoma (ICC) in play this year.
DCTH believes their Ocular Melanoma therapy and Intrahepatic cholangiocarcinoma therapy, combined, tap into a potential market opportunity between:
$452 MILLION - $1.3 BILLION
RES IPSA LOQUITUR
1. DCTH FY 2017 EARNINGS HIGHLIGHTS
• Revenue from European sales for 2017 increased 35%
• Satisfaction of all obligations under the privately placed senior secured convertible notes issued to two institutional investors in June 2016 – DCTH IS DEBT FREE;
• Completed a $5.0 million capital raise in February 2018;
• Modified the Special Protocol Agreement (SPA) with the U.S. Food and Drug Administration (FDA) for the Company’s Phase 3 clinical trial of Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS) to treat patients with hepatic dominant ocular melanoma (OM);
• Announced that the independent Data Safety Monitoring Board (DSMB) of the Phase 3 FOCUS clinical trial recommended that the study continue without modification; Reported the 500th CHEMOSAT treatment in Europe;
• Announced results from a multi-center analysis of Delcath’s Percutaneous Hepatic Perfusion (PHP) therapy in the peer-reviewed Journal of Surgical Oncology; largest data set outside of clinical trial showed manageable toxicity and overall median overall survival of 15.3 months, and;
• Secured a commercial supply of melphalan through an agreement with Tillomed Laboratories for use with the company’s CHEMOSAT® Delivery System for Melphalan, where it is marketed in Europe for the treatment of a wide range of cancers of the liver.
https://finance.yahoo.com/news/delcath-announces-2017-financial-results-130000468.html
2. DCTH IS TELEGRAPHING
Delcath Announces Commercial Supply Agreement for Melphalan Hydrochloride for Injection with Tillomed Laboratories
“We are particularly pleased to be working with a supplier of Tillomed’s caliber and experience as it establishes firm control over our melphalan supply chain in Europe and, over time, will provide economies of scale", noted Jennifer K. Simpson, Ph.D., MSN, CRNP President and CEO of Delcath.
ECONOMIES OF SCALE: A proportionate saving in costs gained by an increased level of production.
Read: Additional supply is needed to match the increased demand for the CHEMSAT therapy.
10K CONFIRMATION:
During 2017, Delcath added 7 employees to support clinical trial implementations in the EU and United States and to meet the demands of commercial sales
http://delcath.com/investors-news/
3. OTHER 10K HIGHLIGHTS
With the establishment of a ZE code for CHEMOSAT, the procedure is now permanently represented in the DRG catalog in Germany.
In the Netherlands CHEMOSAT has been performed at the Netherlands Cancer Institute in 2013 and at Leiden University Medical Centre since 2014. In June 2017 the Medical Oncology National Treatment Guidelines for Uveal Melanoma were updated and now include recommendations to consider CHEMOSAT in the treatment of liver metastases.
4. ICC. In March 2017 we announced another SPA agreement with the FDA for the design of a new pivotal trial of Melphalan/HDS to treat patients with intrahepatic cholangiocarcinoma (ICC). Under the SPA, the Pivotal ICC Trial will enroll approximately 295 ICC patients at approximately 40 clinical sites in the U.S. and Europe. The SPA agreement for this trial indicates that the pivotal trial design adequately addresses objectives that, if met, would support regulatory requirements for approval of Melphalan/HDS in ICC.
5. DARK HORSE. U.S. Right to Try Legislation. Passed Senate. Failed House 3/12/18 (259-140). House leadership will re-submit bill for vote requiring only simple majority. Republicans have simple majority in House. This will pass in time before mid-term elections, IMO.
So what does this mean?
Ocular Melanoma and Intrahepatic cholangiocarcinoma (ICC) are among the most prevalent and lethal forms of cancer. Approval of RIGHT TO TRY would put Ocular Melanoma (FOCUS trial) and Intrahepatic Cholangiocarcinoma (ICC) in play this year.
DCTH believes their Ocular Melanoma therapy and Intrahepatic cholangiocarcinoma therapy, combined, tap into a potential market opportunity is between $452 MILLION - $1.3 BILLION annually.
RES IPSA LOQUITUR
DCTH IS TELEGRAPHING
Delcath Announces Commercial Supply Agreement for Melphalan Hydrochloride for Injection with Tillomed Laboratories
“We are particularly pleased to be working with a supplier of Tillomed’s caliber and experience as it establishes firm control over our melphalan supply chain in Europe and, over time, will provide economies of scale", noted Jennifer K. Simpson, Ph.D., MSN, CRNP President and CEO of Delcath.
ECONOMIES OF SCALE: A proportionate saving in costs gained by an increased level of production.
Read: Additional supply is needed to match the increased demand for the CHEMSAT therapy.
http://delcath.com/investors-news/
------------------------------------------------------------------------
Delcath Systems Offers Significant Upside For Risk-Tolerant Investors
Delcath Systems is developing unique, proprietary medical products which are aimed at treating the unmet needs of patients with liver cancer.
There has been significant regulatory and commercial progress in Europe as well as substantial clinical trial progress in the United States.
Recently released clinical data has provided shareholders with renewed optimism.
Significant potential upside awaits investors who are willing to tolerate the risk associated with this investment.
Delcath Systems (DCTH) offers tremendous potential upside for investors who are willing to tolerate a high degree of risk. Shareholders stand to reap a financial windfall if the company manages to successfully navigate clinical, regulatory, and financial hurdles. Delcath Systems' rock-bottom share price provides investors with the opportunity to initiate a large position in the company and take advantage of this uniquely asymmetric risk/reward opportunity.
https://seekingalpha.com/article/4086621-delcath-systems-offers-significant-upside-risk-tolerant-investors
-----------------------------------------------------------------------
Delcath’s 500th Commercial CHEMOSAT Treatment in Europe:
This is a meaningful milestone for Delcath, one that speaks to the belief physicians in Europe have developed in our product and this therapy for certain types of liver cancers. Our commercialization efforts in Europe have established a considerable body of published and presented research data that demonstrates the safety and efficacy of this therapy in appropriate patients. Further, Dutch Health Authorities recently included CHEMOSAT treatment in their published guidelines for ocular melanoma liver metastases, a step toward potential reimbursement coverage of CHEMOSAT in the Dutch market. We continue to leverage this experience to validate the safety and efficacy of the melphalan/Hepatic Delivery System (CHEMOSAT) in our clinical trials.”
http://delcath.com/reuters-news/?id=2330074
---------------------------------------------------------------------
Positive Results From a Multi-Center Analysis of Delcath PHP Therapy Published in Journal of Surgical Oncology
The study authors further concluded that “results clearly demonstrate that PHP Therapy appears to be an effective means of obtaining rapid intrahepatic disease control, and is a sensible option in patients with predominant liver disease.” Researchers said their results support the use of PHP Therapy in an integrated approach to the management of metastatic ocular melanoma, and looked to the company’s Phase 3 FOCUS Trial to further quantify the benefit and optimize treatment strategies for these patients.
https://www.otcmarkets.com/stock/DCTH/news/Positive-Results-From-a-Multi-Center-Analysis-of-Delcath-PHP-Therapy-Published-in-Journal-of-Surgical-Oncology?id=179899
------------------------------------------------------------------------
Delcath Announces Preliminary Safety Analysis for Phase 3 Focus Trial
“The DSMB’s recommendation to proceed without modification with the FOCUS Trial as planned confirms our own observations of the safety profile of PHP therapy based on prior research and our commercial experience with CHEMOSAT in Europe,” said Jennifer K. Simpson, Ph.D., MSN, CRNP President and CEO of Delcath. “Importantly, this initial independent evaluation of the safety profile of melphalan/HDS used the Generation Two filter configuration of the device and the current version of the procedure protocol, and so provides confidence in both our product and procedure. Given that safety concerns with the previous generation product and procedure were the primary issue in the FDA’s previous assessment, we are pleased to have successfully passed this important milestone.
http://delcath.com/reuters-news/?id=2323336
------------------------------------------------------------------------
Delcath Announces Third Quarter 2017 Financial Results
Highlights from the third quarter of 2017 and recent weeks include:
• Revenue for the third quarter of 2017 increased 75% to $0.7 million from $0.4 million in the prior-year quarter;
• Revenue for the first nine months of 2017 increased 53% to $2.0 million from $1.3 million in the prior-year period;
• Medical University of Hannover achieved its 100th CHEMOSAT treatment milestone; over 450 commercial CHEMOSAT procedures have been performed in Europe;
• Positive results from a single institution study of CHEMOSAT filtration efficiency were presented at 2017 CIRSE annual meeting in September
http://delcath.com/reuters-news/?id=2317164
------------------------------------------------------------------------
Delcath Enhances Board of Directors With Appointment of Industry Veteran, Dr. Simon Pedder
NEW YORK, Nov. 20, 2017 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTHD), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that Simon Pedder, Ph.D., a scientist and pharmaceutical executive with a greater than 30-year career in drug development, has joined the Delcath Board of Directors effective November 14, 2017.
Dr. Pedder currently serves as Chief Business and Strategy Officer at Athenex, Inc., a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer.During his long career in drug development, Dr. Pedder has held several leadership positions including President and CEO of Cellectar Biosciences, President and CEO of Chelsea Therapeutics, Executive Officer and Vice President of Oncology Pharma Business at Hoffmann-LaRoche, Life Cycle Leader and Global Project Leader of Pegasys/IFN and Head of the Hepatitis Franchise at Hoffmann-LaRoche.
http://delcath.com/reuters-news/?id=2317872
Delcath Announces Satisfaction of 2016 Convertible Note
DCTH is now debt free.
http://delcath.com/investors-news/
------------------------------------------------------------------------
Let me be very clear. I DID NOT SELL. I am holding for the long game. DCTH is in no way, shape or form, done.
The only thing that is done is my participation on this message board.
I don’t know about objectivity, but I’ll have more clarity once my FOIA request is answered about a number of DCTH pain points. If you drill deep enough, you will strike oil.
Sam, I hope our paths don’t cross again, truly.
With that, I wish to say farewell DCTH message board; I don’t have anything more to contribute to this forum.
And thank you to those folks who contributed—either bear or bull—to substantive dialogue about DCTH. It was a learning experience.
GLTYA.
True. It could be worse. For example, I could be a complete joke, retired, and yet spend every day blathering gibberish, circular logic and incoherent platitudes on a message board for a stock that, by my own admission, I don’t even own.
We should get movement given the ROTH Conference and more importantly, 4th quarter earnings and management discussion in the 10K.
They are due no later than Friday, March 16th. My money is on the earlier part of the week to coincide with the ROTH Conference.
I think we get some very clear guidance this week, IMO.
From Delcath IR:
Regarding the timing of our 10K filing and year end results, SEC provides 75 days after fiscal year end to file a 10K, and we expect to file and release our 2017 year end results within that window.
Our fiscal year follows the calendar year. Our 4th quarter and 2017 fiscal year just ended.
Regards,
Delcath Investor Relations
investorrelations@delcath.com
www.delcath.com
If you keep drilling, eventually you hit oil.
LoL. That’s a hoot. Let me ask you something, how could it be BVTK?
PR says an unrelated publicly traded corporation. BWAHAHAHAHAHA
Isn’t OOCHIE GOOCHIE CELLUCCI co-CEO of this Cracker Jack outfit?
Doesn't matter where I started buying; I've got a very low PPS avg., all things considered.
Is it miserable being in this spot? Absolutely.
Did I think it would ever crater this low? Nope.
Do I think it will rally? I hope.
But that's life, my friend.
Try to get out and enjoy yourself this weekend. I know I will.
Try telling that to Steve Perry.
The Turn doesn’t believe in facts. Not worth your time, IMO.
Thank you sir. On a side note, not sure if I would have been one of his followers. The thought of "Monk's Den" kinda sorta creeps me out.
Have a good weekend.
Yikes! I don't know much about float lock downs. If anything, the last thing one could say about DCTH is that it is locked down with CDEL, MAXM and this new creeper, BTIG.
I have hopes for next week, truly.
But if it's another channel trading snooze fest, or if one of the creepers conjures up another 50 million shares to dump, it's time to mothball DCTH until Q4.
Good luck and have a nice weekend all.
Hey now! I owned up to value in the fruits of your labor!
Thank you very much for sharing. My bet earnings next Tuesday, before or after the bell. That will give them something to chat about at Tuesday's happy hour and evening entertainment from 6PM-9PM.
Well let’s see if we can close green
today. With earnings next week and CEO at ROTH Conference, I suspect she is acutely aware of what’s on the line here.
She better be.
GLTY
The $64K question. Right now it’s got no debt and $5M in the bank. Spitballing 50M and double/triple that after FDA approval.
Based on the ROTH schedule, between 7 AM - 6 PM next Monday or Tuesday. Without a badge, you’ll need to pull a wedding crasher.
You got this!
Revenue generating biotech business in Europe and on the cusp of FDA approval stateside for a therapy in what will eventually become a $2,500,000,000 (billion) market to treat various liver and colon cancers.
Yet circular Sam thinks the value is at subpenny because, well, that’s where he wants to buy in again.
Dude. Let’s jump into your wormhole: You pimped this stock at a present day value of $422 a share!!!
Now, you believe it’s sub-penny a share?
I’ve come across some characters in my time, sir.
Good point; thanks.
THE BIG QUESTION:
DCTH’s 10K will be issued no later than 16 March, 2018 (next Friday).
What’s the prediction for when the 10K is released? Friday, March 16?
My prediction is dependent on when DCTH presents at the ROTH Conference.
If they present on Monday, earnings after close; If they present on Tuesday, it will be before the bell.
If DCTH has good news to share, it’s going to happen during the ROTH Conference. Not on Sunday—too early. Wednesday? everyone’s too hung over and ready to go home.
Want to get tongues wagging? That’s when you drop it.
BOOM.
Editor’s note: $.0129 a share??? SMH.
Monday, March 12, 2018
6:30AM - 7:00PM Conference Registration and Exhibits
6:30AM - 9:00AM Morning Coffee
7:00AM - 6:00PM Company Presentations & 1-on-1 / Small Group Meetings
12:00PM - 2:00PM Lunch
6:00PM - 9:00PM Evening Entertainment
Tuesday, March 13, 2018
6:30AM - 7:00PM Conference Registration and Exhibits
6:30AM - 9:00AM Morning Coffee
7:00AM - 6:00PM Company Presentations & 1-on-1 / Small Group Meetings
12:00PM - 2:00PM Lunch
4:30PM - 7:00PM Evening Entertainment
OTCQX And OTCQB Companies to Present At 2018 ROTH Conference
https://finance.yahoo.com/news/otcqx-otcqb-companies-present-2018-150000867.html
Are you thinking DCTH unloaded the remaining 70 million AS shares?
Ok; got it. TKS.
Good luck to you.
I assumed those peckers were done weeks ago. Ugh.
Who is out of shares?
Market cap of an oncology biotech generating revenue in Europe that just signed a deal for more DCTH elixir in anticipation (or presently experiencing) increased demand; FDA approval within a year (IMO); and earnings by next Friday according to DCTH IR and the market cap is only $5.2M???
I feel like Mugatu, honestly. Is everyone is taking crazy pills???
I have not voted. I will vote on 5 April.
Earnings are also next week per IR. This hits subpenny this week, come to papa!
My boat is hitched to this hot mess for better, or as it appears now, for worse.
Marking BTIG.
DCTH market cap = $5.9M
SMH. FDA approval around the corner, EU business picking up steam.
Unreal.
Dances, I am with you. Something’s gotta give. The science works. FDA approval close. 500+ CHEMSAT treatments in Europe. New agreement yesterday to increase their drug supply.
Management discussion in the upcoming 10K will tell us everything.
Massive naked short action has been going on for some time. It’s astonishing, quite frankly.
SEC’s own reporting speaks to this (see my post last night) as does the site below.
https://otcshortreport.com/company/DCTH
The difficulty is determining the mechanics. I’ve reached out to the SEC to determine where the data in their reporting comes from. If they can report which settlements failed, they can report from which institutions reported the failure.
Patterns will emerge. They always do.
This is illegal within in the U.S. and this is illegal outside of the U.S.
Naked Short Sales
https://www.sec.gov/answers/nakedshortsale.htm
In a "naked" short sale, the seller does not borrow or arrange to borrow the securities in time to make delivery to the buyer within the standard three-day settlement period.
As a result, the seller fails to deliver securities to the buyer when delivery is due; this is known as a "failure to deliver" or "fail."
SETTLEMENT # FAIL TO DELIVER PRICE AMOUNT
2017-11-10 231,305 $2.18 $504,245
2017-11-20 1,623,353 $0.65 $1,055,179
2017-11-30 1,747,797 $0.12 $209,736
2017-12-04 2,637,662 $0.07 $184,636
2017-12-06 6,738,756 $0.06 $404,325
2017-12-20 1,499,991 $0.06 $89,999
2017-12-21 4,350,241 $0.05 $217,512
2017-12-26 4,330,276 $0.05 $216,514
2018-01-04 8,102,233 $0.05 $405,112
2018-01-10 3,500,006 $0.04 $140,000
2018-01-12 5,669,814 $0.04 $226,793
2018-01-18 5,000,051 $0.04 $200,002
2018-01-24 7,713,444 $0.03 $231,403
The total amount is $3.7M but I have not yet discounted the aggregate calculation of Fails to Deliver for each month, but $2M+ is an entirely defensible number, IMO.
Ha, no. I was taking one about having limited Sam to a one sentence response to a post.